A 59-year-old man is 2 weeks post non-ST-elevation myocardial infarction treated with percutaneous coronary intervention and a drug-eluting stent. He has no major bleeding risk. According to Canadian secondary prevention guidance, what is the most appropriate antiplatelet strategy?